Anticipates record fourth-quarter revenue, expects full-year 2024 revenue of $2.83 billion, submits next- generation Cologuard® to FDA Announces Chief Financial Officer succession plan Highlighted announcements: o o o Expects total fourth quarter revenue of$645.5-$647.5 million, an increase of 17$486.0-$487.0 million and Precision Oncology revenue of$159.5-$160.5 million Expects total full-year 2023 revenue of$2.50 billion and 2024 reven ...